Hepatology CommuniCations Vol 3 8 2019 Mortality Risk Detected Atherosclerotic Cardiovascular Disease Score Patients With Nonalcoholic Fatty Liver Disease 1 Pegah Golabi 2 Natsu Fukui James Paik 2 1 Mehmet Sayiner 2 Alita Mishra Zobair M Younossi 12 Cardiovascular diseases CVDs leading cause mortality patients nonalcoholic fatty liver disease NAFLD Our aim assess association atherosclerotic cardiovascular disease ASCVD risk scores overall cardiacspecific mortality patients NAFLD We National Health Nutrition Examination Survey III National Death Indexlinked mortality files NAFLD defined ultrasound presence steatosis absence secondary causes liver disease High risk CVD defined 10year ASCVD score 75 Hazard ratios HRs populationattributable fractions PAFs high risk CVD calculated Among 1262 subjects NAFLD 479 men 412 white mean age 563 years prevalence high risk CVD 559 48 advanced fibrosis After median followup 177 years 482 subjects 382 died overall causes 382 793 high risk CVD The unadjusted cardiacspecific mortality higher patients NAFLD high risk CVD compared subjects NAFLD low risk CVD 573 vs 168 overall mortality 164 vs 35 cardiovascular mortality After controlling risk factors associated mortality high risk CVD sociated 42 higher overall mortality rate adjusted HR aHR 142 95 confidence interval CI 105 191 twice risk cardiovascular mortality aHR 202 95 CI 112365 Adjusted PAFs 114 overall mortality 449 cardiovascular mortality Conclusion Among patients NAFLD ASCVD score 75 associated higher risk overall cardiacspecific mortality Hepatology Communications 2019310501060 T prevalence nonalcoholic fatty liver dis ease NAFLD increasing worldwide NAFLD considered common cause chronic liver disease devel oped countries Diagnosis NAFLD presence hepatic steatosis histology imaging absence causes fatty liver chronic liver disease 12 3 45 The rising prevalence NAFLD linked alarming rise obesity insulin resistance dia betes mellitus These factors common risk factors NAFLD cardiovascular disease CVD Therefore surprisingly higher prevalence CVD individuals NAFLD compared NAFLD CVD leading cause mortality individuals Abbreviations ACC American College Cardiology AHA American Heart Association aHR adjusted hazard ratio ALT alanine aminotransferase ASCVD atherosclerotic cardiovascular disease AST aspartate aminotransferase BMI body mass index CI confidence interval CKD chronic kidney disease CVD cardiovascular disease FRS Framingham Risk Score HDL highdensity lipoprotein HL hyperlipidemia HR hazard ratio HTN hypertension IDI integrated discrimination improvement MS metabolic syndrome NAFLD nonalcoholic fatty liver disease NFS nonalcoholic fatty liver disease fibrosis score NHANES National Health Nutrition Examination Survey NRI net reclassification improvement PAF populationattributable fraction T2DM type 2 diabetes mellitus Received January 3 2019 accepted May 21 2019 Additional Supporting Information onlinelibrarywileycomdoi101002hep41387suppinfo 2019 The Authors Hepatology Communications published Wiley Periodicals Inc behalf American Association Study Liver Diseases This open access article terms Creat ive Commo ns Attri butio nNonCo mmerc ialNoDerivs License permits use distribution medium provided original work properly cited use noncommercial modifications adaptations View article online wileyonlinelibrarycom DOI 101002hep41387 Potential conflict The authors report 1050 Hepatology CommuniCations Vol 3 8 2019 67 11 10 89 Although growing In context emerging body lit NAFLD erature suggests strong association NAFLD broad spectrum CVDs including premature atherosclerotic heart disease left ven tricular cardiac dysfunction atrial fibrilla tion In fact evidence suggests NAFLD actively involved pathogenesis CVD inde 1213 pendent features metabolic syndrome MS recognition NAFLD commonly encoun tered liver disease clinical practice paucity data guide clinicians risk stratify 1416 patients future risk CVD One widely predictive risk score CVD Framingham Risk Score FRS estimates sexspecific 10year risk coronary heart disease adults known CVD based age smoking status diabetes total cholesterol highdensity lipo protein HDL blood pressure Although FRS widely adopted research clinical practice known limitations derived data exclusively obtained white middleclass population overestimating absolute coronary risk races In context American College Cardiology ACC American Heart Association AHA Task Force released new guideline revised assessment tool estimate 10year lifetime risk developing 19 atherosclerotic cardiovascular disease ASCVD The 2013 ACCAHA guidelines identified 10year risk ASCVD 75 threshold initiating statin therapy In 2018 guide 10year risk CVD categorized lowrisk 5 borderline risk 5 75 intermediate risk 75 20 high risk 20 In recent study South Korea correlation severity hepatic steatosis risk CVD calculated 81718 20 18 21 ASCVD score In study aim determine high ASCVD scores associated increased overall CVD mortality individ uals NAFLD Participants Methods Data souRCe anD population 22 The study cohorts identified National Health Nutrition Examination Survey III NHANES III 19881994 database examined health nutritional status nation ally representative sample approximately 34000 participants United States From 1988 1994 data compiled house hold interviews physical examinations laboratory assays collected blood urine specimens assess prevalence disease disease risk factors nutri tional status civilian noninstitutionalized US population use multistage stratified sampling design The inclusion criteria current analyses chosen match study cohort development ASCVD risk score ACCAHA We restricted analysis adults NAFLD aged 40 74 years history CVD The initial cohort included 19172 adults NHANES III 17367 906 attended examination mobile examination center We excluded 6880 partic ipants blood draws 8hour fasting period 259 positive results hepatitis B surface antigen hepatitis C antibody 406 transferrin saturation 50 1742 ineli gible ultrasound examination age older 75 years younger 20 years 443 ultrasound ungradable missing aRtiCle inFoRmation 1 From Disease Department Medicine Inova Fairfax Hospital Falls Church VA Betty Guy Beatty Center Integrated Research Inova Health System Falls Church VA aDDRess CoRResponDenCe anD RepRint ReQuests Zobair M Younossi MD MPH Claude Moore Health Education Research Building Betty Guy Beatty Center Integrated Research Inova Health System 3300 Gallows Road Falls Church VA 22042 Email ZobairYounossiinovaorg Tel 17037762540 2 Center Liver 1051 GOLABI ET AL 650 significant alcohol consumption 20 g day men 10 g day women We excluded 3356 participants applicable ASCVD risk score age younger 40 years 107 participants missing data components ASCVD risk score 2092 participants NAFLD After previous selfreported CVD excluded 1262 par ticipants NAFLD available analysis Baseline CHaRaCteRistiCs anD DeFinitions The following parameters obtained base line age years raceethnicity Native Americans nonHispanic white nonHispanic black Hispanic race included Asian sex history smoking alcohol consumption selfreported tory CVD cancer selfreported medication use diabetes hypertension HTN hyperlipid emia HL body mass index BMI albumin gdL alanine aminotransferase ALT UL aspartate ami notransferase AST UL transferrin saturation platelet count 1000 cellμL gammaglutamyl tran speptidase UL creatinine mgdL fasting glu cose gdL fasting insulin μlUmL triglycerides mgdL total cholesterol mgdL HDL mgdL lowdensity lipoprotein LDL mgdL hemoglobin A1c HbA1c viral hepatitis serology Diagnosis oF naFlD NAFLD identified presence mild moderate severe hepatic steatosis ultrasound hepatic ultrasound video images Toshiba Sonolayer SSA90A Toshiba video recorders detailed information methodology quality control described absence causes chronic liver disease alcohol consump tion 20 gday male participants 10 gday female participants hepatitis B surface antigen negative antihepatitis C virus antibody negative transferrin saturation 50 23 Hepatology CommuniCations august 2019 participants age race sex smoking sta tus presence diabetes systolic blood pressure antihypertensive medication serum cholesterol HDL levels In study individuals 10year ASCVD risk score 75 referred high risk CVD 19 aDVanCeD FiBRosis By naFlD FiBRosis sCoRe Because liver biopsies available NHANES data sets previously validated 24 noninvasive test NAFLD fibrosis score NFS establish presence advanced fibrosis NFS calculated age BMI diabetes status AST ALT ratio serum albumin platelet count Subjects NAFLD meeting NFS 0676 considered NAFLD advanced fibrosis otHeR DeFinitions 2 25 Chronic kidney disease CKD defined glomerular filtration rate estimated CKD Epidemiology Collaboration equation 60 mL minute173 m urinary albumintocreatinine ratio 30 mgg Obesity defined individuals 2 BMI 30 kgm Type 2 diabetes mellitus T2DM defined fasting glucose level 126 mgdL selfreported medical history diabetes oral hypo glycemic agents insulin use HbA1c 65 HTN defined systolic blood pressure measure 130 mm Hg diastolic blood pressure measurement 80 mm Hg average measurements 26 history high blood pressure measurements HL defined serum cholesterol level 200 mgdL LDL level 130 mgdL HDL level 40 mgdL men 50 women history HL MS defined having following waist circumference 102 cm men 88 cm women fasting plasma glucose 100 mgdL blood pressure 13085 mm Hg tri glycerides 150 mgdL HDL 40 mgdL men 50 mgdL women 27 HigH RisK FoR CVD By asCVD RisK sCoRe The 10year risk developing ASCVD cal culated ASCVD risk score ACCAHA moRtality FolloWup Mortality status NHANES III participants available December 31 2015 considering probabilistic match NHANES III 1052 GOLABI ET AL Hepatology CommuniCations Vol 3 8 2019 28 29 The National Death Index death certificate records 2015 publicuselinked mortality files available Centers Disease Control Prevention website https wwwcdcgovnchsdatalinka gemortality publichtm Followup years overall death cardiac specific deaths collected For cardiacspecific mortality analysis followup continued death attributable CVD censoring time death causes CVD Participants death records presumed alive followup period Because NHANES III completed 6 years time death counted baseline date death 21 years followup whichever came Data analysis Subjects NAFLD categorized groups according ASCVD risk score 75 75 NAFLD characteristics including com ponents ASCVD risk score NFS overall cardiospecific mortality calculated ASCVD risk group Differences groups tested chisquare KruskalWallis test Ageadjusted Cox proportional hazards models estimate hazard ratios HRs 95 confi dence intervals CIs mortality examine baseline risk factors significantly associated end point Risk factors significantly associated mortality bidirectional stepwise selection significance level entry 02 stay 005 added final Cox models calculating HRs populationattributable fraction PAF estimate percentage mor tality reduced avoided specific risk factors removed assumption causal relationship Cardiacspecific cause mortality risks estimated competing risk analysis Mortality resulting causes treated competing risk The proportional hazards assump tion Cox models examined testing time dependent covariates showed significant departure proportionality time To assess reliability predictive accuracy Cox models calibration discrimination consid ered Calibration noted models ability correctly rank subjects risk Discrimination referred power model correctly classify subjects actual outcomes To measure discrimination extended HosmerLemeshow statistical test 30 31 2 survival models conducted A χ value 20 P 005 indicates poor calibration As discrimina tion measure Harrell C statistic survival mod els bootstrapping 1000 replications calculated A C statistic value 07 indicated good model 08 indicated strong model 32 33 As sensitivity analysis tested round ASCVD risk score rulein thresholds determine value returning best possible association mortality We evaluated clinical reclassification Cox model ASCVD risk score 100 model current threshold 75 described survival models The continuous net reclassification improvement NRI inte grated discrimination improvement IDI reported NRI measures net number subjects reclassified correctly new model current model IDI measures improvement new model average sensitivity sacrificing average specificity 34 22 All analyses performed applying sam pling weights stratified design recommended NHANES data As result findings current study generalizable US population We SAS software version 94 SAS Institute Cary NC P 005 consid ered significant Results CHaRaCteRistiCs oF naFlD CoHoRts aCCoRDing asCVD status Of 19172 adults NHANES III final cohort included 1262 participants NAFLD Differences patient demographics comorbidities patients NAFLD overall ASCVD risk group summarized Table 1 Of 1262 patients NAFLD 479 men 412 white mean age 563 years Prevalence high risk CVD 559 patients NAFLD 48 advanced fibrosis Patients NAFLD high risk CVD substantially older 629 vs 488 years likely male individu als 612 vs 329 nonHispanic black 237 vs 171 current smokers 276 vs 128 tak ing antihypertensive medication 372 vs 106 1053 GOLABI ET AL taBle 1 CHaRaCteRistiCs oF aDults ageD 4074 WitH naFlD nHanes iii uniteD states 19881994 Hepatology CommuniCations august 2019 Variables Participants n Age mean SD Male n Race n nonHispanic white nonHispanic black Hispanic BMI mean SD Current smoker n Metabolic components HT HL Diabetes MS Antihypertensive medication n History cancer n Advanced fibrosis n CKD n Laboratory parameters mean SD Albumin gdL AST UL ALT UL Total cholesterol mgdL HDL cholesterol mgdL Systolic blood pressure average Platelet count 1000 cellsμL Mortality data Overall deaths n Cardiacspecific deaths n Cancer deaths n NAFLD 1262 5625 1033 604 4786 520 4120 260 2060 468 3708 3006 596 260 2060 843 6680 1078 8542 293 2322 746 5911 311 2464 94 745 73 590 201 1620 408 034 2244 1089 1974 1372 21853 4281 4704 1439 13202 1847 27658 7076 482 3822 130 1033 132 1046 Atherosclerotic Cardiovascular Disease Risk Score NAFLD With Low Risk CVD NAFLD With High Risk CVD 595 4715 4884 693 196 3294 234 3933 102 1714 248 4168 3024 650 76 1277 295 4958 488 8202 73 1227 268 4504 63 1059 29 487 12 205 49 835 408 034 2281 1242 2112 1593 21153 3957 4926 1464 12296 1409 28834 7139 100 1684 21 354 43 735 667 5285 6286 814 408 6117 286 4288 158 2369 220 3298 2990 542 184 2759 548 8216 590 8846 220 3298 478 7166 248 3718 65 975 61 936 152 2324 408 034 2212 931 1850 1125 22478 4462 4506 1387 14010 1817 26607 6855 382 5727 109 1639 89 1397 P Value 00001 00001 02008 00041 00014 06508 00001 00001 00012 00001 00001 00001 00010 00001 00001 08292 05066 00060 00001 00001 00001 00001 00001 00001 00002 Components ASCVD risk score equation Components NFS equation High risk CVD defined 10year ASCVD risk score 75 Advanced fibrosis defined NFS score 0676 CKD defined estimated glomerular filtration rate 60 mLminute173 m 2 urinary albumintocreatinine ratio 30 mgg compared patients NAFLD lower risk CVD As expected patients NAFLD high risk CVD significantly higher rates MS components obesity T2DM HTN HL comparison patients NAFLD high risk CVD Additionally patients NAFLD high risk CVD sub stantially higher prevalence advanced hepatic fibrosis CKD history cancer Characteristics NAFLD ASCVD risk groups low borderline intermediate high risk reported Supporting Table S1 RisK FaCtoRs oF oVeRall anD CaRDiaCspeCiFiC moRtality naFlD CoHoRts After median followup 177 years NAFLD cohort 482 382 died overall causes 382 793 high risk CVD Of 1054 GOLABI ET AL Hepatology CommuniCations Vol 3 8 2019 decedents 130 270 deaths cardiac specific causes The unadjusted overall cardiac specific mortality higher high risk CVD compared low risk CVD 573 vs 168 overall 164 vs 35 car diacspecific mortality Although cardiac causes leading etiology mortality patients high risk CVD cancerrelated death lead ing cause mortality patients low risk CVD Estimated HRs PAFs risk factor overall cardiacspecific mortality shown Tables 2 3 The analyses new threshold ASCVD risk score 100 overall car diac mortality reported Tables 4 5 oVeRall moRtality After controlling risk factors closely associated mortality increased risk overall mortality independently associated having high risk CVD adjusted HR aHR 142 95 CI 105191 advanced fibrosis aHR 149 95 CI 109202 CKD aHR 188 95 CI 152231 current smoking aHR 164 95 CI 132205 T2DM aHR 132 95 CI 107163 The high est adjusted PAFs overall mortality 161 CKD followed 114 high risk CVD 111 current smoking 85 T2DM 50 advanced fibrosis CaRDiaCspeCiFiC moRtality After controlling risk factors closely associ ated cardiacspecific mortality multivari able Cox model indicated increased risk cardiacspecific mortality independently associated high risk CVD aHR 202 95 CI 112365 CKD aHR 282 95 CI 195408 The highest adjusted PAFs cardiac specific mortality 449 having high risk CVD 287 CKD Notably patients NAFLD high risk CVD cardiac specific mortality patients advanced fibrosis significantly different patients advanced fibrosis 230 vs 161 P 0175 Supporting Table S2 Along advanced fibrosis associated high risk cardiac specific death taBle 2 aDJusteD HRs anD paFs oF inDepenDent RisK FaCtoRs oVeRall moRtality aDults ageD 4074 WitH naFlD Hazard Ratio 95 CI Risk Factors CasesSubjects Age Adjusted Fully Adjusted Adjusted PAF High risk CVD No Yes Advanced fibrosis No Yes CKD No Yes Current smoking No Yes Diabetes No Yes 100594 382667 4141163 5573 3351039 134201 3601001 122260 331969 151292 100 Reference 1925 14632534 100 Reference 1417 1051912 100 Reference 1933 1448258 100 Reference 2058 1682523 100 Reference 1486 10942019 100 Reference 1876 15232312 100 Reference 1842 14972266 100 Reference 1642 13152051 100 Reference 1562 12881894 100 Reference 1316 10651626 114 50 161 111 85 Cox models Adjusted age current smoking status diabetes kidney disease advanced fibrosis high risk CVD High risk CVD defined 10year ASCVD risk score 75 Advanced fibrosis defined NFS score 0676 CKD defined estimated glomerular filtration rate 60 mLminute173 m 2 urinary albumintocreatinine ratio 30 mgg 1055 GOLABI ET AL Hepatology CommuniCations august 2019 taBle 3 aDJusteD HRs anD paFs oF inDepenDent RisK FaCtoRs CaRDiaCspeCiFiC moRtality aDults ageD 4074 WitH naFlD Hazard Ratio 95 CI Risk Factors CasesSubjects Age Adjusted Fully Adjusted Adjusted PAF High risk CVD No Yes CKD No Yes 21593 109665 781036 47201 100 Reference 2239 12693952 100 Reference 2018 11173646 100 Reference 2987 20674318 100 Reference 2820 19494080 449 287 Cox models Adjusted age kidney disease high risk CVD High risk CVD defined 10year ASCVD risk score 75 CKD defined estimated glomerular filtration rate 60 mLminute173 m 2 urinary albumintocreatinine ratio 30 mgg taBle 4 aDJusteD HRs anD paFs oF inDepenDent RisK FaCtoRs oVeRall moRtality aDults ageD 4074 WitH naFlD Best tHResHolD HigH RisK FoR CVD oF 100 Hazard Ratio 95 CI Risk Factors CasesSubjects Age Adjusted Fully Adjusted Adjusted PAF High risk CVD best threshold 100 No Yes Advanced fibrosis No Yes CKD No Yes Current smoking No Yes Diabetes No Yes 136715 346546 4141163 5573 3351039 134201 3601001 122260 331969 151292 100 Reference 100 Reference 319 2165 16832785 1656 12542185 100 Reference 1933 1448258 100 Reference 1517 11162062 100 Reference 2058 1682523 100 Reference 1826 1482225 55 161 100 Reference 100 Reference 105 1842 14972266 1589 12741982 100 Reference 1562 12881894 100 Reference 1253 10121551 74 Cox models Adjusted age current smoking status diabetes kidney disease advanced fibrosis high risk CVD High risk CVD defined 10year ASCVD risk score 100 Advanced fibrosis defined NFS score 0676 CKD defined estimated glomerular filtration rate 60 mLminute173 m 2 urinary albumintocreatinine ratio 30 mgg ValiDation oF tHe neW tHResHolD asCVD RisK sCoRe moRtality Sensitivity analysis showed best association high risk CVD ASCVD score 100 mortality higher aHR 166 95 CI 125219 PAF 319 overall mortality aHR 327 95 CI 188570 PAF 606 cardiacspecific mor 2 tality The comparison HosmerLemeshow χ C statistic Cox models current threshold 75 new threshold 100 2 summarized Table 6 For overall deaths χ indicated 2 good calibration models χ 941 2 P 049 new threshold χ 863 P 057 current threshold Additionally difference 1056 GOLABI ET AL Hepatology CommuniCations Vol 3 8 2019 taBle 5 aDJusteD HRs anD paFs oF inDepenDent RisK FaCtoRs CaRDiaCspeCiFiC moRtality aDults ageD 4074 WitH naFlD Best tHResHolD HigH RisK FoR CVD oF 100 Hazard Ratio 95 CI Risk Factors CasesSubjects Age Adjusted Fully Adjusted Adjusted PAF High risk CVD Best threshold 100 No Yes CKD No Yes 25714 105544 781036 47201 100 Reference 100 Reference 606 3503 20575968 3269 18765697 100 Reference 100 Reference 273 2987 20674318 2607 18013773 Cox models Adjusted age kidney disease high risk CVD High risk CVD defined 10year ASCVD risk score 100 CKD defined estimated glomerular filtration rate 60 mLminute173 m 2 urinary albumintocreatinine ratio 30 mgg taBle 6 summaRy oF peRFoRmanCe oF CoX moDels WitH DiFFeRent tHResHolDs oF asCVD RisK sCoRe HosmerLemeshow χ 2 P Value C Statistic 95 CI NRI Total EventsNonevents IDI Absolute Relative Overall deaths Model threshold 75 Model threshold 100 Cardiacspecific deaths Model threshold 75 Model threshold 100 863 0567 941 0493 319 0922 241 0966 0755 07300778 0757 07320782 0790 07490831 0799 07600838 Reference 12 5240 Reference 52 564 Reference 1 4 Reference 2 9 Adjusted age current smoking status diabetes kidney disease advanced fibrosis high risk CVD Adjusted age kidney disease high risk CVD C statistics different thresholds values 0757 95 CI 07320782 new threshold 0755 95 CI 07300778 current threshold We improvements model new threshold current The NRI 12 event NRI 52 nonevent NRI 40 overall deaths 52 event NRI 56 nonevent NRI 4 cardiacspecific deaths The absolute relative IDI indexes 1 4 respectively overall death 2 9 respec tively cardiacspecific deaths Discussion In study populationbased database explore overall cardiacspecific mortality large cohort adult subjects NAFLD Our data showed overall cardiacspecific mortality significantly higher patients NAFLD ASCVD score 75 indicates high risk CVD 10 years In context compared patients NAFLD high risk CVD patients NAFLD high risk CVD NAFLD ASCVD 75 vs NAFLD ASCVD 75 demonstrated presence ASCVD 75 associated 3 times higher risk cardiacspecific mortality Furthermore elimination high risk CVD subjects NAFLD result 61 lower cardiacspecific mortal ity risk This important highly relevant cardiovascular mortality main cause death NAFLD changes ASCVD risk scores substantial cardiac benefits patients 35 1057 GOLABI ET AL Hepatology CommuniCations august 2019 studies determined association ASCVD risk score mortality patients NAFLD Additionally study pro vides unique opportunity assess interaction ASCVD scores noninvasive fibrosis scores NAFLD combined effect mortality On hand study lim itations First able establish diag nosis NAFLD ultrasound nonalcoholic steatohepatitis requires histologic confirmation Also ASCVD risk score developed 2013 accuracy applicability different populations 41 established Although ASCVD risk score aims improve generalizability multiethnic populations applicability outside United States needs established Finally caveat NHANES III oversampling Mexican Americans limiting generaliz ability findings raceethnicity groups progression rates chronic liver diseases vary different ethnicities The association ASCVD risk score liverrelated mortality evaluated unavailability specific cause death publicuse mortality files 4344 42 14424550 In summary NAFLD highly prevalent proportion patients developing liver dis ease On hand cardiovascular mortality main cause death NAFLD predictive models ASCVD risk score provide easy tool identify patients NAFLD greatest risk CVD This lead ability potentially modify risks pos sibly change longterm cardiovascular outcomes Acknowledgment We thank Deena Hallaji Brian Lam Beatty Liver Obesity Research Program staff librarians Inova Fairfax Hospital support formation study ReFeRenCes 1 Sayiner M Koenig A Henry L Younossi ZM Epidemiology nonalcoholic fatty liver disease nonalcoholic steatohepatitis United States rest world Clin Liver Dis 201620205214 2 Younossi Z Anstee QM Marietti M Hardy T Henry L Eslam M et al Global burden NAFLD NASH trends predic tions risk factors prevention Nat Rev Gastroenterol Hepatol 2018151120 3 Chalasani N Younossi Z Lavine JE Charlton M Cusi K Rinella M et al The diagnosis management nonalco holic fatty liver disease practice guidance American 38 39 83637 Risk assessment CVD undertaken number scores ASCVD score FRS In previous studies FRS associated severity steatosis noninvasive markers fibrosis NFS mortality NAFLD Given limitation FRS ACC AHA developed ASCVD risk score com prehensive tool assess 10year lifetime risk cardiovascular events In context study confirms value ASCVD score patients NAFLD In fact patients NAFLD ASCVD 75 higher risk cardiacspecific mortality higher risk overall mortality These data provide simple noninvasive method determine patients NAFLD greatest risk cardiovascular mortality overall mortality In context individuals approached clinically optimize management cardiovascular risks potentially lower future risk cardiovascular mortality In addition NFS establish associ ation high risk CVD ASCVD score 75 advanced fibrosis As expected patients NAFLD ASCVD 75 showed sig nificantly higher rates advanced hepatic fibrosis More importantly patients ASCVD 75 presence advanced fibrosis signif icant impact overall mortality In fact patients NAFLD ASCVD 75 advanced fibrosis highest risk overall mortality In contrast observation true cardiac specific mortality One possible explanation finding patients ASCVD 75 increased risk cardiacspecific mortality presence advanced fibrosis add additional risks Our finding supported recent study Hagstrom et al evaluated liver histology traditional cardiovascular risk fac tors predictor CVD outcomes patients biopsyproven NAFLD This study concluded CVD risk factors taken account presence nonalcoholic steatohepatitis advanced fibrosis associated incident CVD risk patients NAFLD However studies assessing association severity hepatic fibrosis CVD risk needed 40 It important emphasize important findings study First knowledge 1058 GOLABI ET AL Hepatology CommuniCations Vol 3 8 2019 Association Study Liver Diseases Hepatology 201867328357 4 Ballestri S Zona S Targher G Romagnoli D Baldelli E Nascimbeni F et al Nonalcoholic fatty liver disease asso ciated twofold increased risk incident type 2 diabetes metabolic syndrome Evidence sys tematic review metaanalysis J Gastroenterol Hepatol 201631936944 5 Younossi ZM Nonalcoholic fatty liver disease global public health perspective J Hepatol 201970531544 6 Fargion S Porzio M Fracanzani AL Nonalcoholic fatty liver disease vascular disease stateoftheart World J Gastroenterol 2014201330613324 7 Ma J Hwang SJ Pedley A Massaro JM Hoffmann U Chung RT et al Bidirectional analysis fatty liver cardio vascular disease risk factors J Hepatol 201766390397 8 Treeprasertsuk S Leverage S Adams LA Lindor KD St Sauver J Angulo P The Framingham risk score heart disease nonalcoholic fatty liver disease Liver Int 201232945950 9 Lonardo A Sookoian S Chonchol M Loria P Targher G Cardiovascular systemic risk nonalcoholic fatty liver dis ease atherosclerosis major player natural course NAFLD Curr Pharm Des 20131951775192 10 Granér M Nyman K Siren R Pentikäinen MO Lundbom J Hakkarainen A et al Ectopic fat depots left ventricular function nondiabetic men nonalcoholic fatty liver dis ease Circ Cardiovasc Imaging 20148piie001979 11 Käräjämäki AJ Pätsi OP Savolainen M Kesäniemi YA Huikuri H Ukkola O Nonalcoholic fatty liver disease pre dictor atrial fibrillation middleaged population OPERA Study PLoS One 201510e0142937 12 Targher G Lonardo A Byrne CD Nonalcoholic fatty liver dis ease chronic vascular complications diabetes mellitus Nat Rev Endocrinol 20181499114 13 Lonardo A Nascimbeni F Mantovani A Targher G Hypertension diabetes atherosclerosis NASH cause sequence J Hepatol 201868335352 14 Targher G Day CP Bonora E Risk cardiovascular disease patients nonalcoholic fatty liver disease N Engl J Med 201036313411350 15 Lonardo A Ballestri S Targher G Loria P Diagnosis man agement cardiovascular risk nonalcoholic fatty liver disease Expert Rev Gastroenterol Hepatol 20159629650 16 Bazick J Donithan M NeuschwanderTetri BA Kleiner D Brunt EM Wilson L et al Clinical model NASH advanced fi brosis adult patients diabetes NAFLD guidelines referral NAFLD Diabetes Care 20153813471355 17 Pastori D Loffredo L Perri L Baratta F Scardella L Polimeni L et al Relation nonalcoholic fatty liver disease Framingham Risk Score flowmediated dilation patients cardiomet abolic risk factors Am J Cardiol 201511514021406 18 Schlendorf KH Nasir K Blumenthal RS Limitations Framingham risk score clearer Prev Med 200948115116 19 Goff DC Jr LloydJones DM Bennett G Coady S DAgostino RB Gibbons R et al American College Cardiology American Heart Association Task Force Practice Guidelines 2013 ACCAHA guideline assessment cardiovas cular risk report American College Cardiology American Heart Association Task Force Practice Guidelines Circulation 2014129Suppl 2S49S73 Erratum Circulation 2014129Suppl 2S74S75 20 Grundy SM Stone NJ Bailey AL Beam C Birtcher KK Blumenthal RS et al 2018 AHAACCAACVPRAAPA ABCACPMADAAGSAPhAASPCNLAPCNA guide line management blood cholesterol executive summary report American College CardiologyAmerican Heart Association Task Force Clinical Practice Guidelines J Am Coll Cardiol 2018piiS0735109718390338 21 Lee JI Kim MC Moon BS Song YS Han EN Lee HS et al The relationship 10year cardiovascular risk calculated pooled cohort equation severity nonalcoholic fatty liver disease Endocrinol Metab Seoul 2016318692 22 US Department Health Human Services Vital health statistics Sample design National Health Nutrition Examination Survey httpwwwcdcgovnchsdata serie ssr_02sr02_113pdf Published September 1992 Accessed August 2016 23 National Center Health Statistics National Health Nutrition Examination Survey NHANES III Hepatic ste atosis ultrasound images assessment procedures manual https wwwcdcgovnchsdatanhane snhane s3hepat ic_steat osis_ ultra sound_proce dures_manualpdf Published November 2010 Accessed February 2019 24 Angulo P Hui JM Marchesini G George J Farrell GC Enders F et al The NAFLD fibrosis score noninvasive identifies liver fibrosis patients NAFLD Hepatology 200745846854 25 Levey AS Stevens LA Schmid CH Zhang YL Castro AF 3rd Feldman HI et al CKDEPI Chronic Kidney Disease Epidemiology Collaboration A new equation estimate glo merular filtration rate Ann Intern Med 2009150604612 26 Whelton PK Carey RM Aronow WS Casey DE Jr Collins KJ Dennison Himmelfarb C et al 2017 ACCAHAAAPAABC ACPMAGSAPhAASHASPCNMAPCNA guideline prevention detection evaluation management high blood pressure adults report American College CardiologyAmerican Heart Association Task Force Clinical Practice Guidelines J Am Coll Cardiol 201871e127e248 Erratum J Am Coll Cardiol 20187122752279 27 Expert Panel Detection Evaluation Treatment High Blood Cholesterol Adults Executive Summary Third Report National Cholesterol Education Program NCEP Expert Panel Detection Evaluation Treatment High Blood Cholesterol Adults Adult Treatment Panel III JAMA 200128524862497 28 National Center Health Statistics NCHS 2011 linked mortality files matching methodology httpwwwcdcgov nchsdatadatal inkag e2011_linked_morta lity_f ile_match ing_metho dologypdf Published September 2013 Accessed February 2018 29 National Center Health Statistics Codebook 2105 publicuse linked mortality file LMF https wwwcdcgov nchsdatadatal inkag epublicuse2015linkedmorta lityfiles datadicti onarypdf Published February 13 2019 Accessed February 28 2019 30 Spiegelman D Hertzmark E Wand HC Point interval es timates partial population attributable risks cohort studies examples software Cancer Causes Control 200718571579 31 Allison PD Survival analysis SAS System practical guide Cary NC SAS Publishing 1995 32 Andersen PK Regression modeling strategies applica tions linear models logistic regression survival analysis Frank E Harrell Jun SpringerVerlag New York 2001 Book Review Stat Med 20032225312532 33 Hosmer DW Lemeshow S Applied Logistic Regression Second Edition Hoboken NJ John Wiley Sons 2000 34 Pencina MJ DAgostino RB Sr Steyerberg EW Extensions net reclassification improvement calculations measure useful ness new biomarkers Stat Med 2011301121 35 Younossi Z Tacke F Arrese M Sharma BC Mostafa I Bugianesi E et al Global perspectives nonalcoholic fatty 1059 GOLABI ET AL liver disease nonalcoholic steatohepatitis Hepatology 2018 doihttps doiorg101002hep30251 36 Corey KE Chalasani N Management dyslipidemia car diovascular risk factor individuals nonalcoholic fatty liver disease Clin Gastroenterol Hepatol 20141210771084 37 Ioannou GN Weiss NS Boyko EJ Mozaffarian D Lee SP Elevated serum alanine aminotransferase activity calculated risk coronary heart disease United States Hepatology 20064311451151 38 Dogan S Celikbilek M Yilmaz YK Sarikaya S Zararsiz G Serin HI et al Association liver fibrosis coronary heart disease risk patients nonalcoholic fatty liver disease Eur J Gastroenterol Hepatol 201527298304 39 Menon VP Edathadathil F Sathyapalan D Moni M Don A Balachandran S et al Assessment 2013 AHAACC ASCVD risk scores behavioral characteristics urban cohort India preliminary analysis noncommunicable disease initiatives research AMrita NIRAM study Medicine Baltimore 201695e5542 40 Hagström H Nasr P Ekstedt M Hammar U Stål P Askling J et al Cardiovascular risk factors nonalcoholic fatty liver disease Liver Int 201939197204 41 DeFilippis AP Young R Carrubba CJ McEvoy JW Budoff MJ Blumenthal RS et al An analysis calibration discrim ination multiple cardiovascular risk scores modern multiethnic cohort Ann Intern Med 2015162266275 42 Kavousi M Leening MJ Nanchen D Greenland P Graham IM Steyerberg EW et al Comparison application ACCAHA guidelines Adult Treatment Panel III guide lines European Society Cardiology guidelines car diovascular disease prevention European cohort JAMA 201431114161423 43 Younossi ZM Stepanova M Hepatitis C virus infection age Hispanic ethnicity increase mortality liver cancer United States Clin Gastroenterol Hepatol 20108718723 Hepatology CommuniCations august 2019 44 Williams CD Stengel J Asike MI Torres DM Shaw J Contreras M et al Prevalence nonalcoholic fatty liver disease nonalcoholic steatohepatitis largely middleaged population utilizing ultrasound liver biopsy prospective study Gastroenterology 2011140124131 45 Younossi Z Stepanova M Ong JP Jacobson IM Bugianesi E Duseja A et al Global Nonalcoholic Steatohepatitis Council Nonalcoholic steatohepatitis fastest growing cause hepatocellular carcinoma liver transplant candidates Clin Gastroenterol Hepatol 201917748755e3 46 Golabi P Stepanova M Pham HT Cable R Rafiq N Bush H et al Nonalcoholic steatofibrosis NASF independently predict mortality patients nonalcoholic fatty liver dis ease NAFLD BMJ Open Gastroenterol 20185e000198 47 Golabi P Otgonsuren M Avila L Sayiner M Rafiq N Younossi ZM Components metabolic syndrome increase risk mortality nonalcoholic fatty liver disease NAFLD Medicine Baltimore 201897e0214 48 Younossi ZM Stepanova M Rafiq N Henry L Loomba R Makhlouf H et al Nonalcoholic steatofibrosis independently predicts mortality nonalcoholic fatty liver disease Hepatol Commun 20171421428 49 Younossi ZM Loomba R Anstee QM Rinella ME Bugianesi E Marchesini G et al Diagnostic modalities nonalcoholic fatty liver disease nonalcoholic steatohepatitis associated fibrosis Hepatology 201868349360 50 Younossi ZM Henry L Bush H Mishra A Clinical eco nomic burden nonalcoholic fatty liver disease nonalcoholic steatohepatitis Clin Liver Dis 201822110 Supporting Information Additional Supporting Information onlinelibrarywileycomdoi101002hep41387suppinfo 1060 GOLABI ET AL